Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-focused microcap is building a treasury strategy centered on accumulating BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Grace Therapeutics Inc GRCE

Healthcare Biotechnology
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a... see more

Recent & Breaking News (NDAQ:GRCE)

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

GlobeNewswire 3 days ago

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

GlobeNewswire March 19, 2026

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

GlobeNewswire February 25, 2026

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

GlobeNewswire February 12, 2026

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

GlobeNewswire November 17, 2025

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

GlobeNewswire November 13, 2025

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

GlobeNewswire November 11, 2025

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

GlobeNewswire October 23, 2025

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

GlobeNewswire September 22, 2025

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

GlobeNewswire September 18, 2025

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 4, 2025

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

GlobeNewswire August 27, 2025

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

GlobeNewswire August 12, 2025

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

GlobeNewswire June 25, 2025

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

GlobeNewswire June 23, 2025

Grace Therapeutics to Participate in the 2025 BIO International Conference

GlobeNewswire June 13, 2025

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

GlobeNewswire April 9, 2025

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

GlobeNewswire March 11, 2025

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

GlobeNewswire February 25, 2025

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

GlobeNewswire February 13, 2025

Podcasts